Go To Global Site
Welcome to UCB in the United States

Nov

12

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

Nov

05

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

1200x675.UCB_LOGO_TAG_C_RGB_600.jpg

Sep

22

UCB Achieves Important Regulatory Milestone for Bimekizumab

  • The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
  • This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara® (ustekinumab) and Humira® (adalimumab) in achieving skin clearance at week 16

Aug

31

Press Release: Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry

  • Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure (PGTCS) during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period compared with placebo 

Jul

29

Press Release: UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer’s Disease

UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer’s Disease

Jul

24

Press Release: Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance

Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance

Apr

02

UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients

UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients.

Dec

09

Press Release: UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

Dec

06

Press Release: Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®

Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®

Nov

15

Press Release: Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study

• The Phase 3 BE READY study, evaluating the efficacy and safety of bimekizumab versus placebo in adults with moderate-to-severe chronic plaque psoriasis, met all primary and ranked secondary endpoints1
• UCB plans to submit applications to regulatory authorities for approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020